GlassScriptPhysician profile
Rian Nina M Jaffer
NPI 1841407798
$4,340.12
in general payments reported to CMS, 2019-2025
24 companies · $617 in 2025
The $617 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $1,208 · 2023: $675 · 2024: $818 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.87 |
| Education | $188.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $627.92 | 2021-2025 | Adbry |
| Abbvie INC. | $498.53 | 2021-2024 | |
| Janssen Biotech, INC. | $491.34 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $479.65 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $386.63 | 2021-2025 | |
| Ucb, INC. | $252.13 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $233.15 | 2021-2025 | |
| Pfizer INC. | $188.31 | 2021-2023 | |
| Lilly USA, LLC | $187.06 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $160.67 | 2023-2024 | Odomzo |
| Biofrontera INC. | $127.68 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Epi Health, LLC | $107.64 | 2021-2022 | |
| Amgen INC. | $89.37 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $83.68 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $75.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.76 | 2025 | Spevigo |
| Nabriva Therapeutics, Plc | $49.57 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.15 | 2021 | |
| Incyte Corporation | $25.15 | 2025 | Opzelura |
| Paratek Pharmaceuticals, INC. | $21.51 | 2024 | Nuzyra |
| Galderma Laboratories, L.P. | $15.67 | 2025 | Nemluvio |
| Organogenesis INC. | $14.90 | 2025 | Cygnus Dual |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rian Nina Jaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.